IPO Year:
Exchange: NASDAQ
8-K/A - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)
8-K - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)
10-Q - FIREFLY NEUROSCIENCE, INC. (0000803578) (Filer)
3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
3 - FIREFLY NEUROSCIENCE, INC. (0000803578) (Issuer)
SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)
SC 13G - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)
SC 13D - FIREFLY NEUROSCIENCE, INC. (0000803578) (Subject)
TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a strategic partnership with Zeto, Inc. ("Zeto"), a leading innovator in EEG brain monitoring technology. Under the agreement, Firefly will act as a non-exclusive distributor of Zeto's FDA-cleared EEG headset devices, cloud platform and services, expanding Firefly's accessibility to healthcare providers and institutions. This collaboration will also integrate Firefly's proprietary Brain Network
TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that its Chief Executive Officer, Jon Olsen, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024. Mr. Olsen will discuss recent corporate milestones, including closing the merger transaction with WaveDancer and Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) platform. The Com
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced management will host a shareholder update call on Wednesday, September 4, 2024 at 5:00 PM Eastern Time. Event: Firefly Neuroscience Shareholder Update Date: Wednesday, September 4, 2024Time: 5:00 PM ESTWebinar Registration Link: https://us02web.zoom.us/webinar/register/WN_uUqPh-uSRhyYX0nzBrrh3w#/registration About FireflyFirefly (NASDAQ:AIFF) is an Artificia
TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced that it has formed a strategic partnership with the Neurology Consultants of Dallas ("NCD") to help enhance early detection efforts and disease management for patients suffering from cognitive decline. NCD will incorporate Firefly's Brain Network Analytics ("BNA") technology into its patient workflow and conduct clinical studies aimed at identifying biomarkers
TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced the appointment of Stella Vnook, Ph.D. to its Board of Directors, effective as of August 19, 2024. Dr. Vnook will serve as Chairperson of the Nominating Committee. Dr. Vnook brings over 25 years of experience as a distinguished pharmaceutical executive, serial entrepreneur, CEO and founder of multiple biotech companies and visionary leader with a track record of success in biotechnology and life